Q4 2025 BioInvent International AB Earnings Call Transcript
Key Points
- BioInvent International AB (FRA:BIX0) reported strong data for its lead candidate BI-1808 in T-cell lymphoma, presented at ASH 2025.
- The company initiated a phase 2A trial for BI-1206 in combination with pembrolizumab for non-small cell lung cancer and uveal melanoma.
- BioInvent received orphan drug designation from the EMA for BI-1808 for the treatment of cutaneous T-cell lymphoma.
- The company announced promising data from its ongoing phase 2A study for BI-1808 with Keytruda in recurrent ovarian cancer.
- BioInvent nominated two new board members with strong profiles in the pharma and biotech industry, enhancing its leadership team.
- Net sales for Q4 2025 decreased significantly to SEK3 million from SEK21.4 million in Q4 2024.
- The decrease in net sales was attributed to lower production of antibodies for customers in 2025.
- Operating costs increased by SEK62 million from 2024 to 2025, impacting the company's financial performance.
- The company reported a negative result of minus SEK125.8 million for Q4 2025.
- BioInvent's financial outlook indicates the need for additional funding or partnerships to sustain operations beyond the next 12 months.
Welcome to BioInvent Year-end Report 2025.
(Operator Instructions)
Now I will hand the conference over to the speakers, CEO Martin Welschof and CFO Stefan Ericsson. Please go ahead.
Thank you and welcome everybody to our year end report. Today is February 26, 2026.
And as usual I will start with the summary.
So, we had a couple of key events in the fourth quarter. First of all, the two ASH data set.
So, with BI-1808, our lead candidate targeting TNF receptor 2, we saw very strong data in the T-cell lymphoma, and we presented that at ASH 2025 and then come back to the data a little bit more in detail later.
And then we had another F presentation about, BI-1206 which is our lead targeting FC gamma-2B, in combination with rituximab and Calquenc in, non-Hodgkinâs Lymphoma, and that was also presented at ASH 2025 and, also very strong data set. I should mention that year 1808, that was a monotherapy, single agent therapy.
Then we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
